Sohee Oh1, Sungjun Choi2, Hyun-Sun Yoon2,3. 1. Department of Biostatistics, SMG-SNU Boramae Medical Center, Seoul, Korea. 2. Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. 3. Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. hyunsun.yoon@snu.ac.kr.
Abstract
BACKGROUND: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not. OBJECTIVE: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA). METHODS: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019. RESULTS: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively. CONCLUSION: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.
BACKGROUND: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not. OBJECTIVE: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA). METHODS: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019. RESULTS: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively. CONCLUSION: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.
Authors: Z Z N Yiu; K J Mason; P J Hampton; N J Reynolds; C H Smith; M Lunt; C E M Griffiths; R B Warren Journal: Br J Dermatol Date: 2020-03-30 Impact factor: 9.302
Authors: Alan Menter; Joel M Gelfand; Cody Connor; April W Armstrong; Kelly M Cordoro; Dawn M R Davis; Boni E Elewski; Kenneth B Gordon; Alice B Gottlieb; Daniel H Kaplan; Arthur Kavanaugh; Matthew Kiselica; Dario Kivelevitch; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Craig L Leonardi; Jason Lichten; Henry W Lim; Nehal N Mehta; Amy S Paller; Sylvia L Parra; Arun L Pathy; Elizabeth Farley Prater; Robert S Rahimi; Reena N Rupani; Michael Siegel; Benjamin Stoff; Bruce E Strober; Elliot B Tapper; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Craig A Elmets Journal: J Am Acad Dermatol Date: 2020-02-28 Impact factor: 11.527
Authors: R G Langley; M Lebwohl; G G Krueger; P O Szapary; Y Wasfi; D Chan; M C Hsu; Y You; Y Poulin; N Korman; J C Prinz; K Reich Journal: Br J Dermatol Date: 2015-03-22 Impact factor: 9.302
Authors: R Bissonnette; T Luger; D Thaçi; D Toth; A Lacombe; S Xia; R Mazur; M Patekar; P Charef; M Milutinovic; C Leonardi; U Mrowietz Journal: J Eur Acad Dermatol Venereol Date: 2018-03-22 Impact factor: 6.166